Retia Medical Systems, Inc.

Retia Medical Systems develops cardiovascular surveillance software and hemodynamic monitoring solutions for intensive care, operating rooms, and perioperative environments. The company's core offering is the Argos® Cardiac Output Monitor, a bedside hemodynamic monitoring device that derives reliable cardiac output and cardiovascular insight from routine physiologic signals without requiring proprietary disposable sensors. The Argos Infinity™ platform extends this capability enterprise-wide, deploying the company's Multi-Beat Analysis (MBA) algorithm across hospital systems and tele-ICU environments to enable centralized cardiovascular surveillance and analytics. Retia's technology is designed to detect hemodynamic instability earlier than traditional vital sign monitoring, particularly in complex scenarios including arrhythmia, cardiogenic shock, low-flow states, and unstable blood pressure. The software integrates with existing monitoring and tele-ICU platforms, transforming real-time physiologic data into actionable clinical intelligence. Deployed in 75+ hospitals including major academic medical centers (Johns Hopkins, Duke Health, Cleveland Clinic, University Hospitals Cleveland, Texas Health Resources, UMC Health System, Rabin Medical Center), the solution has been validated in 14 peer-reviewed clinical studies. Retia received FDA 510(k) clearance for Argos Infinity. The company targets high-risk populations including cardiac and vascular surgery, sepsis, transplant, trauma, burns, and neurocritical care. Primary value propositions include elimination of disposable sensor costs, intuitive bedside workflow design, and system-wide scalability without infrastructure burden.